EGFR and hepatocellular carcinoma: Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis further elucidated the mechanistic involvement of benzoxazinone derivatives in HCC therapy, identifying six key pathways: cancer‐associated signaling (23 targets), proteoglycans in cancer (16), ErbB signaling (9), PI3K‐Akt pathway (14), EGFR tyrosine kinase inhibitor (TKI) resistance (8), and VEGF signaling (7) (Figure S10).